Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC, is developing products to treat anemias, cancers and their debilitating comorbidities.  A portfolio of hematology and oncology products is in development.

  • The company’s lead product, SANGUINATE™, is in clinical testing, focused on treating the comorbidities of sickle cell disease and other disorders caused by anemia or hypoxia/ischemia
  • EPEG® is a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy
  • Other products are in development for comorbidities that result from cancer



Originally established in 2005 as a research lab, Prolong has emerged as a mature privately held biotech company. Led by a team of successful pharmaceutical executives, Prolong has multiple clinical development programs and large scale cGMP manufacturing facilities in production.


The Prolong leadership has led and been associated with a number of successful pharmaceutical and biotechnology companies. The team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide.

© Copyright - 2015, Prolong Pharmaceuticals, LLC. All Rights Reserved.
"circle P" logo, Prolong Pharmaceuticals, SANGUINATE, PPBD, "treating comorbidities", and "treating the comorbidities of sickle cell disease" are trademarks or registered trademarks of Prolong Pharmaceuticals.